Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.

RATIONALE: Increased vascularity and expression of vascular endothelial growth factor (VEGF) are recognized features of the asthmatic airway. The association of vascular remodeling with airway hyperresponsiveness (AHR) is unclear. OBJECTIVE: To assess vascular remodeling and sputum VEGF concentrati...

Bibliografski detalji
Glavni autori:	Siddiqui, S, Sutcliffe, A, Shikotra, A, Woodman, L, Doe, C, McKenna, S, Wardlaw, A, Bradding, P, Pavord, I, Brightling, C
Format:	Journal article
Jezik:	English
Izdano:	2007

Slični predmeti

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
od: Brightling, C, i dr.
Izdano: (2003)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
od: Berry, M, i dr.
Izdano: (2004)

Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects.
od: Woodman, L, i dr.
Izdano: (2006)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
od: Brightling, C, i dr.
Izdano: (1999)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
od: Brightling, C, i dr.
Izdano: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
od: Brightling, C, i dr.
Izdano: (2000)

Observational study of the natural history of eosinophilic bronchitis.
od: Berry, M, i dr.
Izdano: (2005)

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.
od: Brightling, C, i dr.
Izdano: (2002)

Eosinophilic bronchitis is an important cause of chronic cough.
od: Brightling, C, i dr.
Izdano: (1999)

Eosinophilic bronchitis - what is it and why is it important?
od: Brightling, C, i dr.
Izdano: (2000)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
od: Green, R, i dr.
Izdano: (2002)

Mepolizumab in refractory eosinophilic asthma.
od: Pavord, I, i dr.
Izdano: (2010)

Eosinophilic bronchitis: an important cause of prolonged cough.
od: Brightling, C, i dr.
Izdano: (2000)

Non-eosinophilic corticosteroid unresponsive asthma.
od: Pavord, I, i dr.
Izdano: (1999)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
od: Berry, M, i dr.
Izdano: (2007)

Eosinophilic bronchitis: clinical features, management and pathogenesis.
od: Birring, S, i dr.
Izdano: (2003)

The significance of eosinophilic airway inflammation in asthma
od: Pavord, I, i dr.
Izdano: (2002)

Eosinophils in asthma and other allergic diseases.
od: Wardlaw, A, i dr.
Izdano: (2000)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
od: Kulkarni, N, i dr.
Izdano: (2010)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
od: Haldar, P, i dr.
Izdano: (2009)

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.
od: Brightling, C, i dr.
Izdano: (2000)

Eosinophils in asthma and airway hyperresponsiveness.
od: Brightling, C, i dr.
Izdano: (2004)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
od: Bilocca, D, i dr.
Izdano: (2017)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
od: Shrimanker, R, i dr.
Izdano: (2017)

Airway hyperresponsiveness is dissociated from airway wall structural remodeling.
od: Siddiqui, S, i dr.
Izdano: (2008)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
od: Haldar, P, i dr.
Izdano: (2014)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
od: Shrimanker, R, i dr.
Izdano: (2017)

New insights into the role of the mast cell in asthma.
od: Brightling, C, i dr.
Izdano: (2003)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
od: Haldar, P, i dr.
Izdano: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
od: Haldar, P, i dr.
Izdano: (2014)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
od: Berry, M, i dr.
Izdano: (2005)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
od: Brightling, C, i dr.
Izdano: (2004)

Glucocorticoids and mepolizumab in eosinophilic asthma.
od: Bel, E, i dr.
Izdano: (2014)

Chapter 11. Mast cell localization within the airway smooth muscle: Relationship to airway hyperresponsiveness and other asthma phenotypes
od: Wardlaw, A, i dr.
Izdano: (2004)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
od: Yancey, S, i dr.
Izdano: (2016)

Mast-cell infiltration of airway smooth muscle in asthma.
od: Brightling, C, i dr.
Izdano: (2002)

Biomarkers for severe eosinophilic asthma.
od: Yancey, S, i dr.
Izdano: (2017)

New insights into the relationship between airway inflammation and asthma.
od: Wardlaw, A, i dr.
Izdano: (2002)

Non-eosinophilic asthma and the innate immune response.
od: Pavord, I
Izdano: (2007)

Mepolizumab, quality of life, and severe eosinophilic asthma.
od: Pavord, I
Izdano: (2017)